Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance

Open access
Herman, William H., Hoerger, Thomas J., Brandle, Michael, Hicks, Katherine, Sorensen, Stephen, Zhang, Ping, Hamman, Richard F., Ackermann, Ronald T., Engelgau, Michael M., Ratner, Robert E., for the Diabetes Prevention Program Research Group* · 2005 · Annals of Internal Medicine

Abstract

BACKGROUND: The Diabetes Prevention Program (DPP) demonstrated that interventions can delay or prevent the development of type 2 diabetes. OBJECTIVE: To estimate the lifetime cost-utility of the DPP interventions. DESIGN: Markov simulation model to estimate progression of disease, costs, and quality of life. DATA SOURCES: The DPP and published reports. TARGET POPULATION: Members of the DPP cohort 25 years of age or older with impaired glucose tolerance. TIME HORIZON: Lifetime. PERSPECTIVES: Health system and societal. INTERVENTIONS: Intensive lifestyle, metformin, and placebo interventions as implemented in the DPP. OUTCOME MEASURES: Cumulative incidence of diabetes, microvascular and neuropathic complications, cardiovascular complications, survival, direct medical and direct nonmedical costs, quality-adjusted life-years (QALYs), and cost per QALY. RESULTS OF BASE-CASE ANALYSIS: Compared with the placebo intervention, the lifestyle and metformin interventions were estimated to delay the development of type 2 diabetes by 11 and 3 years, respectively, and to reduce the absolute incidence of diabetes by 20% and 8%, respectively. The cumulative incidence of microvascular, neuropathic, and cardiovascular complications were reduced and survival was improved by 0.5 and 0.2 years. Compared with the placebo intervention, the cost per QALY was approximately 1100 dollars for the lifestyle intervention and $31 300 for the metformin intervention. From a societal perspective, the interventions cost approximately 8800 dollars and 29,900 dollars per QALY, respectively. From both perspectives, the lifestyle intervention dominated the metformin intervention. RESULTS OF SENSITIVITY ANALYSIS: Cost-effectiveness improved when the interventions were implemented as they might be in routine clinical practice. The lifestyle intervention was cost-effective in all age groups. The metformin intervention did not represent good use of resources for persons older than 65 years of age. LIMITATIONS: Simulation results depend on the accuracy of the underlying assumptions, including participant adherence. CONCLUSIONS: Health policy should promote diabetes prevention in high-risk individuals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-142-5-200503010-00007

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Research works printed but not linked: 3

  1. 10.1037/0022-006X.69.4.717 · doi:10.1037/0022-006x.69.4.717 · Paper page
  2. Laupacis A, 1992, CMAJ, 146, 473
  3. 10.1001/archinte.1992.00400150120022 · doi:10.1001/archinte.1992.00400150120022 · Paper page

Cited by

See all 703

Metadata

Authors
Herman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., Hamman, R. F., Ackermann, R. T., Engelgau, M. M., Ratner, R. E., & for the Diabetes Prevention Program Research Group*
Affiliations
  • Centers for Disease Control and Prevention (US)
  • From University of Michigan Health System, Ann Arbor, Michigan; RTI International, Research Triangle Park, North Carolina; Centers for Disease Control and Prevention, Atlanta, Georgia; University of Colorado Health Sciences Center, Denver, Colorado; Indiana University School of Medicine, Indianapolis, Indiana; and Medstar Research Institute, Hyattsville, Maryland.
Venue
Annals of Internal Medicine
Published
2005-03-01
Volume
142
Issue
5
Pages
323-332
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2001192679
Cited by
703
References
45
Citations by year
2026: 8 · 2025: 13 · 2024: 20 · 2023: 23 · 2022: 14 · 2021: 31 · 2020: 30 · 2019: 22 · 2018: 28 · 2017: 31 · 2016: 33 · 2015: 35 · 2014: 39 · 2013: 43 · 2012: 39
FWCI
121.42
Type
journal article
Language
en
Open access
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (U01DK048489)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes prevention, impaired glucose tolerance, metformin, intensive lifestyle intervention, cost-effectiveness, quality-adjusted life years, Diabetes Prevention Program, microvascular complications, cardiovascular complications, diabetes incidence, older adults
MeSH terms
Adult, Aged, Computer Simulation, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Diet, Reducing, Humans, Hypoglycemic Agents, Life Style, Markov Chains, Metformin, Middle Aged, Sensitivity and Specificity, Exercise, Glucose Intolerance, Disease Progression, Quality-Adjusted Life Years

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance. https://app.cochat.ai/papers/10.7326/0003-4819-142-5-200503010-00007
The paper
Herman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., Hamman, R. F., Ackermann, R. T., Engelgau, M. M., Ratner, R. E., & for the Diabetes Prevention Program Research Group*. (2005). The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-142-5-200503010-00007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.